Join this interactive deep dive on microbial biomarkers to understand the future of the microbiome in precision medicine in IBD to enable us to better stratify patients and improve therapeutic efficacy to enhance patient care.

Unmissable highlights:

• Gain insight on how we measure the microbiome and our current understanding of the role of the microbiome in IBD: healthy host-microbiome interactions and how they are dysregulated in IBD, evidence for microbial associations with IBD from cross-sectional human studies (IBD versus healthy, responder versus non-responder), if time: evidence from IBD-relevant preclinical models
• Understanding microbiome heterogeneity and the potential but also caveats of incorporating microbiome variability into therapeutic or biomarker strategy, progress toward identifying predictive and prognostic biomarkers
• Discussion of Genentech’s efforts to utilize patient and microbiome data from ph3 trials toward reverse translation and biomarker identification
• Looking toward the future: microbiome measurements beyond shotgun metagenomic sequencing